Feb 10 (Reuters) - Ocean Biomedical OCEA.O:
OCEAN BIOMEDICAL ANNOUNCES BREAKTHROUGH FINDINGS IN EGFR-MUTANT LUNG CANCER AND PLANS FOR FDA ALIGNMENT ON NEXT-STAGE DEVELOPMENT
OCEAN BIOMEDICAL- TO INITIATE PRECLINICAL STUDIES TO ADVANCE IMMUNOTHERAPY PROGRAM & TO ENGAGE WITH FDA FOR FIRST-IN-HUMAN TRIALS
Source text: ID:nGNX9fMqJF
Further company coverage: OCEA.O